Warning: Cannot modify header information - headers already sent by (output started at D:\InetPub\vhosts\sourcejuice\wp-config.php:1) in D:\InetPub\vhosts\sourcejuice\wp-content\themes\classic\postdetail_new2.php on line 3
IMS Report: U.S. prescription drug sales slowdown

IMS Report: U.S. prescription drug sales slowdown

April 19, IMS Global Medical Health Information Institute (hereinafter referred to as "IMS Institute") published in 2010, the U.S. pharmaceutical market the amount of prescription drug sales increased by 2.3%, significantly lower than the annual growth rate of 5.9% in 2009 (see Figure 1) . IMS Research Institute in its latest report - "2010 Annual Review of U.S. drug use" that U.S. prescription drug sales in 2010 reached 3,074 billion U.S. dollars; per capita pharmaceutical spending $ 898, compared with 2009 growth of $ 6; 2010, U.S. prescription drug sales the amount of overall growth at historical low levels.

Figure: China market and the growth of prescription drug sales

IMS Research and Development Institute, Mr. MichaelKleinrock head said: "caused by the 2010 slowdown in the U.S. pharmaceutical market, the impact of factors including: increased use of generic drugs, brand drug patents expire, and the listing of new drugs to reduce demand and consumption. In addition, perhaps is affected by the economic crisis last year, a visit to a doctor's patients to reduce the number, accept the new numbers of patients with chronic diseases also declined. "

IMS Research Institute pointed out in the latest impact of the U.S. pharmaceutical market growth include:

Drug Sales: 2010 oral or nasal drug absorption drug delivery sales rose 0.5%, down 0.3% in per capita terms, because almost every major therapeutic areas of demand have declined. Muscular or intravenous mode of administration of drugs sales rose 0.2%, 0.6% decline in per capita terms, this is caused due to decrease in the use of hospital equipment.

Access to doctors and the number of patients starting new therapy: 2010 to the hospital clinics 4.2% reduction in the number of patients, extending from mid-2009, the downward trend. At the same time last year, a new therapy in patients with chronic diseases to reduce the number 3400000. The main reason may include the high unemployment rate and rising medical costs, more patients have lost health insurance for health care spending more cautious.

Payment patients: 2010 patients with an average payment amount of $ 10.73, down 20 cents year on year in 2009, mainly due to the increased use of generic drugs. Patients with third-party commercial insurance to pay 63% of the prescriptions, 66% less than 5 years ago. PartD plan or health insurance for Medicaid reimbursement of prescriptions for 30% of total prescriptions, while in 2006 the insurance program has just started, compared to 22%.

Drug Pricing: In 2010, oral or inhaled drug delivery of drugs (accounting for 60% of total expenditure of drugs), the average cost decreased by 0.1% due to price changes of its generic drugs and patent medicines and combination sales. Muscular or intravenous mode of administration of drugs (28% of total expenditure), the cost increase of 5.7%. The invoice price changes in 2010 for the protected brand name drugs expenditure 16.6 billion, 15.8 billion in 2009 dollars. Cause of this growth is due to pay and the circulation of discounts and rebates on invoices outside the negotiations to increase, resulting in a net increase of $ 12,100,000,000 pricing, 4.2% of total expenditure.

Retail sales: a total of 3.99 billion in 2010 prescriptions through retail channels settlement, chain drug stores to become more and more patient choice, which reflects the convenience of Chain Drug Stores and the effectiveness of generic discount. In addition, the increasing number of independent pharmacies were chain pharmacies acquisition, the drugstore chain market share in 2010 increased 0.5%.

New products: new listings in 2010 a total of 44 patented drugs, 10 of which use an innovative new drug mechanism of action, including a new oral treatment for multiple sclerosis therapy, a treatment for osteoporosis and bone disease monoclonal antibodies and the treatment for prostate cancer vaccine. In addition, 5 "orphan drugs", and 6 with the known mechanism of the chemical structure of the new drugs are successful listing last year, as rheumatoid arthritis, and meningitis in patients with prostate cancer provides a new treatment option. In the past 24 months for each new drug listed, the average sales of 6,200 million U.S. dollars, down from 114 million in 2006. This reflects the trend is the new mechanism of drug administration medications known to orphan drugs and new chemical structure, mechanism of action of drug changes.

Patented drugs and generic drugs: patent medicine in 2010 for spending fell 0.7%, while for the brand and non-branded generic drugs expenditure increased by 4.5% and 21.7%. Generic drugs now account for 78% of all retail prescriptions, this is due to more patent expired drugs to market generic form, and patients tend to choose low-cost generic drugs. Usually the patent expired in 6 months, more than 80% of the patents will be generic prescription drugs instead.

IMS Institute study also found that the leading therapeutic area in 2010 sales growth was mainly due to changes in the product life cycle driven, rather than its prices or sales. In 2010 the top five therapeutic areas are: sales of 22.3 billion antineoplastic; respiratory system drug sales of 19.3 billion U.S. dollars; lipid regulator sales of 18.7 billion U.S. dollars; hypoglycemic agents, and sales of 16.9 billion anti-psychotic Drug sales of 16.1 billion U.S. dollars (see Table 1). Among them, the blood lipid regulator an increase of 0.9%, an increase of 12.5% ​​hypoglycemic agents. It is noteworthy that sales grew only 3.5% of anticancer drugs is the lowest growth in the fields of history.

Mr. Kleinrock said: "field of health care changes in 2010, especially, more treatment options available to doctors and patients, as well as by the patent expired and the brand-name drugs in patients with active medication reduced the impact of prescription drugs up to a record low value-added. the number of doctors visits and a decline in new therapies for patients with long-term health effects is still unclear and requires close attention. "